Pharming Group announces the 2024 Annual General Meeting of Shareholders
April 04 2024 - 2:30AM
Pharming Group announces the 2024 Annual General Meeting of
Shareholders
Leiden, The Netherlands, April 4, 2024:
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext
Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024
Annual General Meeting of Shareholders (the “AGM”) will be held on
Tuesday, May 21, 2024 at 14:30 CEST. The Notice to Convene,
Explanatory Notes, Proxy and other meeting documents for the AGM
can be found on the Company’s website under Investors/Shareholder
Meetings.
The agenda of the AGM includes the reappointment
of Ms. Barbara Yanni and Mr. Mark Pykett as Non-Executive Directors
for periods of four years, (ii) the adoption of the updated
Remuneration Policy for members of the Board of Directors (iii) the
authorization for the Board of Directors to issue shares and/or
options, and to restrict or exclude pre-emptive rights in relation
thereto, up to 10% of the issued share capital for general
corporate purposes, including issuances for M&A transactions
and issuances pursuant to equity incentive plans and (iv) the
authorization for the Board of Directors to repurchase shares.
The AGM will be held at the Corpus Congress
Centre, Willem Einthovenstraat 1, 2342 BH in Oegstgeest, the
Netherlands, and will be webcast live.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam:
PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated
to transforming the lives of patients with rare, debilitating, and
life-threatening diseases. Pharming is commercializing and
developing an innovative portfolio of protein replacement therapies
and precision medicines, including small molecules, biologics, and
gene therapies that are in early to late-stage development.
Pharming is headquartered in Leiden, Netherlands, and has employees
around the globe who serve patients in over 30 markets in North
America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and
find us on LinkedIn.
Inside Information
This press release relates to the disclosure of
information that qualifies, or may have qualified, as inside
information within the meaning of Article 7(1) of the EU Market
Abuse Regulation.
For further public information,
contact:
Pharming Group, Leiden, The
NetherlandsMichael Levitan, VP Investor Relations &
Corporate CommunicationsT: +1 (908) 705 1696E:
investor@pharming.com
FTI Consulting, London, UKVictoria
Foster Mitchell/Alex Shaw/Amy ByrneT: +44 203 727 1000
LifeSpring Life Sciences Communication,
Amsterdam, The NetherlandsLeon MelensT: +31 6 53 81 64
27E: pharming@lifespring.nl
Pharming Group NV (EU:PHARM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Pharming Group NV (EU:PHARM)
Historical Stock Chart
From Nov 2023 to Nov 2024
